MDA 19 is primarily researched for its potential use in scientific studies related to cannabinoid receptors. It is often explored for its binding affinity to CB1 and CB2 receptors, which are part of the endocannabinoid system. This makes it a candidate for understanding receptor interactions and signaling pathways. Additionally, it may be studied for its effects on neurological conditions or pain management, though its applications remain largely experimental. Researchers also investigate its structural properties to develop novel compounds with therapeutic potential.